.svg){kind=small}
Aug-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Market Insights Snapshot
MediPharm Labs concentrated 91.77% of August 2026 sales in Oil, where year-over-year sales fell 20.03% and month-over-month declined 2.08%, while Vapor Pens held 6.25% share with a 51.42% year-over-year drop but a 0.20% month-over-month uptick; Edible contracted to 1.21% share with a 67.68% year-over-year slide and a 43.41% month-over-month fall, and Capsules represented 0.77% share with a 46.28% year-over-year decline and a 13.12% month-over-month decrease. With Oil ranked 1 in Alberta and the brand’s average price down 5.13% year over year to $41.83, the pattern implies an Oil-centric footprint that is defending rank in certain markets while peripheral categories are shrinking faster, concentrating exposure to a single category.
The tightening mix into Oil alongside a modest month-over-month dip of 2.08% in that category and a 0.20% month-over-month lift in Vapor Pens implies that incremental gains will come from defending premium-priced Oil while selectively testing adjacent inhalables rather than spreading into weaker, faster-declining formats like Edible at -43.41% month over month. Given brand-level year-over-year sales at -24.70% against a 20.03% decline in Oil and a 51.42% decline in Vapor Pens, the brand’s positioning is anchored to maintaining Oil leadership and price architecture, using targeted innovation to offset volatility in smaller categories without diluting share where the brand already ranks 1.
Competitive Landscape
MediPharm Labs ranks #3 in ON Oil in August 2026, unchanged from #3 year over year, and also steady versus three months ago at #3, while its historical peak was #2 in December 2024; in contrast, Mod climbed from #2 to #1 with approximately 41.9% year-over-year sales growth and Redecan slipped from #1 to #2 alongside a 24.4% sales decline, signaling that MediPharm Labs’ flat rank amid a leadership swap above it and 27.7% growth from NightNight at #4 implies a defended share position but rising pressure from both an accelerating leader and a faster-moving challenger.
Notable Products
CBN/CBD 1:2 Relax Formula Oil (30ml) posted the largest movement in August 2026 with a +54.0% month-over-month surge that lifted it to rank 3, while THC Dissolving Drops Oil (30ml) fell -26.3% to rank 4. The top two positions were held by CBN:THC 1:2 Nighttime Formula Oil (30ml) at rank 1 with a -7.1% decline and THC 30 Regular Formula Oil (30ml) at rank 2 with a -0.2% slip, indicating momentum is shifting within the oil lineup toward mixed-cannabinoid formulas. With eight of the top ten SKUs in Oils and CBD 50 Plus Olive Formula Oil (30ml) also down -19.4% at rank 5, the gains in the CBN/CBD segment offset weakness in several THC-forward and olive-formula Oils. The pattern implies MediPharm Labs is pivoting toward multi-cannabinoid Oils that can grow share even as legacy THC and olive variants contract.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
